These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 34391396)

  • 1. Secular trends and regional variations in pharmacotherapy of attention-deficit/hyperactivity disorder (ADHD) among children and adolescents in Germany.
    Akmatov MK; Holstiege J; Bätzing J
    BMC Psychiatry; 2021 Aug; 21(1):405. PubMed ID: 34391396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The 10-year trend in drug prescriptions for attention-deficit/hyperactivity disorder (ADHD) in Germany.
    Grimmsmann T; Himmel W
    Eur J Clin Pharmacol; 2021 Jan; 77(1):107-115. PubMed ID: 32803292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative treatment patterns, healthcare resource utilization and costs of atomoxetine and long-acting methylphenidate among children and adolescents with attention-deficit/hyperactivity disorder in Germany.
    Greven P; Sikirica V; Chen YJ; Curtice TG; Makin C
    Eur J Health Econ; 2017 Sep; 18(7):893-904. PubMed ID: 27817164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug prescription for attention deficit hyperactivity disorder drugs in pediatric outpatients: A retrospective survey of Japanese administrative data (2012-2018).
    Kikuchi D; Obara T; Tokunaga M; Shiozawa M; Takahashi A; Ito M; Hino H; Miura R; Hayakawa S; Watanabe Y
    Asian J Psychiatr; 2021 Mar; 57():102512. PubMed ID: 33486336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prescribing patterns for attention deficit hyperactivity disorder among children and adolescents in Taiwan from 2004 to 2017.
    Liao HC; Lin FJ; Hsu CN; Gau SS; Wang CC
    J Formos Med Assoc; 2023 Jun; 122(6):514-517. PubMed ID: 36931958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The epidemiology of pharmacologically treated attention deficit hyperactivity disorder (ADHD) in children, adolescents and adults in UK primary care.
    McCarthy S; Wilton L; Murray ML; Hodgkins P; Asherson P; Wong IC
    BMC Pediatr; 2012 Jun; 12():78. PubMed ID: 22712630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prescribing patterns for attention deficit hyperactivity disorder medications among children and adolescents in Korea, 2007-2011.
    Song I; Shin JY
    Epidemiol Health; 2016; 38():e2016045. PubMed ID: 27866408
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Children with Attention-Deficit/Hyperactivity Disorder.
    Shang CY; Pan YL; Lin HY; Huang LW; Gau SS
    J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):566-73. PubMed ID: 26222447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Injury prevention by medication among children with attention-deficit/hyperactivity disorder: a case-only study.
    Mikolajczyk R; Horn J; Schmedt N; Langner I; Lindemann C; Garbe E
    JAMA Pediatr; 2015 Apr; 169(4):391-5. PubMed ID: 25686215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined methylphenidate and atomoxetine pharmacotherapy in attention deficit hyperactivity disorder.
    Ozbaran B; Kose S; Yuzuguldu O; Atar B; Aydin C
    World J Biol Psychiatry; 2015; 16(8):619-24. PubMed ID: 26223958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Age-related pharmacotherapy of attention deficit hyperactivity disorder in Slovenia in children and adolescents: A population-based study.
    Stuhec M; Locatelli I
    Eur Psychiatry; 2017 May; 42():129-133. PubMed ID: 28371725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential therapeutic effects of 12-week treatment of atomoxetine and methylphenidate on drug-naïve children with attention deficit/hyperactivity disorder: A counting Stroop functional MRI study.
    Chou TL; Chia S; Shang CY; Gau SS
    Eur Neuropsychopharmacol; 2015 Dec; 25(12):2300-10. PubMed ID: 26409297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trends in attention-deficit/hyperactivity disorder drug consumption in children and adolescents in Slovenia from 2001 to 2012: a drug use study from a national perspective.
    Štuhec M; Locatelli I; Švab V
    J Child Adolesc Psychopharmacol; 2015 Apr; 25(3):254-9. PubMed ID: 25803789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug Prescriptions for Children With ADHD in Japan: A Study Based on Health Insurance Claims Data Between 2005 and 2015.
    Yoshida M; Obara T; Kikuchi S; Satoh M; Morikawa Y; Ooba N; Yamaguchi H; Mano N
    J Atten Disord; 2020 Jan; 24(2):175-191. PubMed ID: 31056996
    [No Abstract]   [Full Text] [Related]  

  • 15. Differences in Utilization Patterns among Medications in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: a 36-Month Retrospective Study Using the Korean Health Insurance Review and Assessment Claims Database.
    Bhang SY; Hwang JW; Kwak YS; Joung YS; Lee S; Kim B; Sohn SH; Chung US; Yang J; Hong M; Bahn GH; Choi HY; Oh IH; Lee YJ
    J Korean Med Sci; 2016 Aug; 31(8):1284-91. PubMed ID: 27478341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Attention deficit hyperactivity disorder in childhood and adolescence : Current state of research].
    Häge A; Hohmann S; Millenet S; Banaschewski T
    Nervenarzt; 2020 Jul; 91(7):599-603. PubMed ID: 32270222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Seasonal Patterns of Medications for Treating Attention-Deficit/Hyperactivity Disorder: Comparison of Methylphenidate and Atomoxetine.
    Shyu YC; Lee SY; Yuan SS; Yang CJ; Yang KC; Lee TL; Wang LJ
    Clin Ther; 2016 Mar; 38(3):595-602. PubMed ID: 26874787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attention deficit hyperactivity disorder pharmacotherapy in Slovenian adults: a population-based study.
    Stuhec M; Locatelli I
    Int J Clin Pharm; 2018 Apr; 40(2):341-344. PubMed ID: 29468526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Age-specific prevalence, incidence of new diagnoses, and drug treatment of attention-deficit/hyperactivity disorder in Germany.
    Lindemann C; Langner I; Kraut AA; Banaschewski T; Schad-Hansjosten T; Petermann U; Petermann F; Schreyer-Mehlhop I; Garbe E; Mikolajczyk RT
    J Child Adolesc Psychopharmacol; 2012 Aug; 22(4):307-14. PubMed ID: 22856384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attention-deficit hyperactivity disorder, its pharmacotherapy, and the risk of developing bipolar disorder: A nationwide population-based study in Taiwan.
    Wang LJ; Shyu YC; Yuan SS; Yang CJ; Yang KC; Lee TL; Lee SY
    J Psychiatr Res; 2016 Jan; 72():6-14. PubMed ID: 26519764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.